Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Sets New 1-Year High – What’s Next?

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) reached a new 52-week high during trading on Tuesday . The company traded as high as $14.55 and last traded at $14.11, with a volume of 1491914 shares trading hands. The stock had previously closed at $13.58.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the company. Zacks Research raised Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, January 20th. Barclays raised Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a research note on Tuesday, January 6th. Morgan Stanley raised shares of Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a report on Wednesday, December 3rd. Finally, JPMorgan Chase & Co. upgraded shares of Bayer Aktiengesellschaft from a “neutral” rating to an “overweight” rating in a research report on Monday, December 8th. Three equities research analysts have rated the stock with a Strong Buy rating and four have given a Buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Buy”.

Bayer Aktiengesellschaft Stock Performance

The firm’s 50-day simple moving average is $11.95 and its two-hundred day simple moving average is $9.49. The stock has a market capitalization of $56.59 billion, a PE ratio of -159.98, a PEG ratio of 4.88 and a beta of 0.67. The company has a current ratio of 1.14, a quick ratio of 0.71 and a debt-to-equity ratio of 1.10.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.